Please assess the completion status of the following clinical trial:

Trial Title: CCR2 AAA Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Non-Aneurysmal Patients, (Aim 2A, n=3)~Inclusion Criteria:~- Patients with aortoiliac occlusive disease causing lifestyle limiting claudication, rest pain, and/or tissue loss that requires aortofemoral bypass~Exclusion Criteria:~- Patients with aortoiliac occlusive disease, we will apply the same exclusion criteria as AAA patients.~Abdominal Aortic Aneurysm (AAA) Patients, (Aim 2B, n=5)~Inclusion Criteria:~* We will recruit asymptomatic patients with known AAAs by ultrasound, Doppler, and CT (men ≥ 5.5 cm, women ≥ 5.0cm);~* Both men and women, between the ages of 45 -75;~* With or without active tobacco use;~Exclusion Criteria:~* Inability to receive and sign informed consent;~* Has a history of hypersensitivity to contrast agent, Iopamidol (Isovue)~* Patients with Stage ≥ 4 chronic renal failure (calculated by modification of diet in renal disease eGFR equation \[to minimize confounding imaging variables\]);~* Inability to tolerate 60 minutes in a supine position with arms down at sides, as necessary for PET/CT;~* Severe claustrophobia;~* Positive pregnancy test or lactating;~* Has a history of hypersensitivity to 64Cu-DOTA-ECL1i or any of its excipients;~* Any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as: Symptomatic/recently treated coronary disease, cancer requiring oncologic management, or autoimmune/inflammatory diseases (e.g., rheumatoid arthritis or multiple sclerosis) that are known to have increased associated expression of CCR2.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AAA Group (Type: ACTIVE_COMPARATOR): Participants with AAA will undergo routine clinical evaluation of AAA including ultrasound and CT and scheduling of open surgical repair as directed by the treating physician. We will record age and tobacco use of participant. If participant has not had a renal function blood test performed within the past 90 days, we will draw approximately 2 teaspoons of blood for a creatinine test. We will also ask the participant's permission to use a contrast dye for the CT portion of the PET-CT scan. If the participant agrees we will additional questions to gauge eligibility to receive the contrast dye.~If available, we would like to collect any discarded AAA tissue from the surgical procedure. This discarded tissue will be kept as part of a Washington University vascular research repository. If the participant agrees to this there will be a separate consent form to sign allowing the collection of the leftover tissue along with some information about medical history.
- Aortoiliac Occlusive Disease Group (Type: ACTIVE_COMPARATOR): Participants with non-aneurysmal aortoiliac occlusive disease, will be eligible for the study based on lifestyle limiting claudication (lack of blood flow to muscles causing cramping), pain in the feet or toes at rest, and/or tissue loss (leg or foot ulcers that don't heal or gangrene) that requires aortofemoral bypass. The aortofemoral bypass is not part of this research study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues